Alpha 2.0
Login Register
» Articles » PMID: 21242480

Overview of the 2010 Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee Meeting Regarding Ticagrelor

Overview
Journal Circulation
Specialty Cardiology & Vascular Diseases
Date 2011 Jan 19
PMID 21242480
Citations 10
Authors
Michael A Gaglia Jr
Ron Waksman
Affiliations
Soon will be listed here.
Citing Articles

Ticagrelor inhibits the NLRP3 inflammasome to protect against inflammatory disease independent of the P2Y signaling pathway.

Huang B, Qian Y, Xie S, Ye X, Chen H, Chen Z Cell Mol Immunol. 2020; 18(5):1278-1289.

PMID: 32523112 PMC: 8093290. DOI: 10.1038/s41423-020-0444-5.

Total cardiovascular events analysis of the EXAMINE trial in patients with type 2 diabetes and recent acute coronary syndrome.

Cavender M, White W, Liu Y, Massaro J, Bergenstal R, Mehta C Clin Cardiol. 2018; 41(8):1022-1027.

PMID: 29652078 PMC: 6489788. DOI: 10.1002/clc.22960.

Ticagrelor therapy and atrioventricular block: Do we need to worry?.

De Maria E, Borghi A, Modonesi L, Cappelli S World J Clin Cases. 2017; 5(5):178-182.

PMID: 28560235 PMC: 5434317. DOI: 10.12998/wjcc.v5.i5.178.

Spontaneous hematoma in the setting of dual anti-platelet therapy with ticagrelor: A case report.

Feng C, Wang L, Wang L Oncol Lett. 2016; 12(1):144-146.

PMID: 27347115 PMC: 4907270. DOI: 10.3892/ol.2016.4552.

Towards personalized medicine based on platelet function testing for stent thrombosis patients.

Godschalk T, Hackeng C, Ten Berg J Thrombosis. 2013; 2012:617098.

PMID: 23320159 PMC: 3540832. DOI: 10.1155/2012/617098.